Company Filing History:
Years Active: 2015
Title: Sherrye Glaser: Innovator in Endocannabinoid Research
Introduction
Sherrye Glaser is a prominent inventor based in Dix Hills, NY (US). She has made significant contributions to the field of endocannabinoid research, particularly through her innovative patent that addresses the modulation of endocannabinoid levels in subjects.
Latest Patents
Sherrye Glaser holds a patent titled "Fatty acid binding proteins as drug targets for endocannabinoids." This invention provides a method for modulating the level of an endocannabinoid in a subject by administering an effective amount of an agent that inhibits the interaction of the endocannabinoid with an intracellular fatty acid binding protein (FABP). The patent outlines various methods for identifying agents that can modulate the levels of endocannabinoids and fatty acid amides, which are crucial for treating neurological disorders. The invention emphasizes the role of specific fatty acid binding proteins, including FABP3, FABP5, and FABP7, in this modulation process.
Career Highlights
Sherrye Glaser is affiliated with the State University of New York, where she continues her research and development in the field of endocannabinoids. Her work has garnered attention for its potential applications in treating various diseases and disorders.
Collaborations
Some of her notable coworkers include Dale Deutsch and Martin Kaczocha, who have collaborated with her on research related to fatty acid binding proteins and their implications in drug development.
Conclusion
Sherrye Glaser's innovative work in the modulation of endocannabinoids through her patented methods highlights her significant role in advancing medical research. Her contributions pave the way for potential treatments for neurological disorders, showcasing the importance of her research in the scientific community.